MannKind vs OPKO Health
MNKD and OPK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MNKD and OPK compare
MannKind and OPKO Health are about the same size, with market caps of $1.3B and $1.2B.
MannKind grew revenue faster over the last twelve months (30.5% versus −11.5% for OPKO Health).
MannKind keeps more of each dollar of sales as profit, with a net margin of −11.1% compared with −12.4% at OPKO Health.
OPKO Health scores higher on the StockData Score (9 against 6 for MannKind), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MNKD | OPK |
|---|---|---|
| Size and price | ||
| Market cap | $1.3B | $1.2B |
| Share price | $3.96 | $1.62 |
| Change, 1 year | −22.0% | 26.6% |
| Change, 5 years | −14.6% | −60.8% |
| Beta (5Y) | 2.02 | 0.36 |
| Employees | 241 | 2,275 |
| StockData Score | ||
| Total score | 6 | 9 (better) |
| Valuation score | 1 | 1 |
| Growth score | 2 (better) | 1 |
| Performance score | 2 | 3 (better) |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.2× | 2.1× (better) |
| P/B | – | 1.0× |
| EV/EBITDA | 38.6× | 22.0× (better) |
| FCF yield | −1.4% (better) | −11.1% |
| Fair value | $1.80 | $1.55 |
| Margin of safety | −120% | −4.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 30.5% (better) | −11.5% |
| Revenue growth, 5Y average | 39.9% (better) | −15.8% |
| Net income growth (TTM) | −233% | – |
| EPS growth (TTM) | −218% | – |
| Profitability | ||
| Gross margin | 89.8% (better) | 40.8% |
| Operating margin | 2.3% (better) | −8.2% |
| Net margin | −11.1% (better) | −12.4% |
| FCF margin | −4.6% (better) | −22.8% |
| Return on equity | – | −5.9% |
| Return on invested capital | – | −4.0% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Net debt / EBITDA | – | −7.19 |
| Interest coverage | 0.3× | – |
| Current ratio | 1.72 | 3.35 (better) |
| Altman Z-score | −4.48 | −0.21 (better) |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | 3.9% |
| Shareholder yield | 0.00% | 3.9% (better) |
| Ownership | ||
| Held by institutions | 56.7% | 27.2% |
| Held by insiders | 2.5% | 43.6% |
| Insider net buying, 12 months | −$2.9M | −$13.2K (better) |
| Short interest, % of float | 8.4% | 7.8% |
Go deeper
- MNKD stock overview
- MNKD income statement
- MNKD valuation and score
- OPK stock overview
- OPK income statement
- OPK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.